FDA approves Ferring's generic DDAVP

WASHINGTON Ferring Pharmaceuticals has received approval from the Food and Drug Administration for its application for desmopressin acetate tablets.

Desmopressin is the generic of Aventis Pharamceuticals DDAVP.

The drug is indicated as an antidiuretic replacement therapy in the management of central diabetes insipidus, which is abnormal urine output, and for the management of the temporary polyuria, abnormal urine output, and polydipsia, drinking abnormal amounts of fluids, following head trauma or surgery in the pituitary region. The drug is also used in the management of primary nocturnal enuresis and to determine the capacity of the kidney to concentrate urine in pediatric patients.